^
    9ms
    CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML (clinicaltrials.gov)
    P1, N=16, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    CART-33
    over1year
    CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, University of Pennsylvania
    New P1 trial • Combination therapy
    |
    CART-33
    2years
    G-CSF Mobilized Apheresis As an Alternative Source of CAR T-Cells (ASH 2022)
    Methods Untransduced T-cells (UTD) and CAR T-cells targeting CD33 (CART33) were manufactured using paired steady state (ss) cells and cells collected after rhG-CSF treatment (mob)...Successful completion of this work may support the use of cryopreserved G-CSF stimulated apheresis units for cell therapy applications. This may allow for an adjunct cell therapy to hematopoietic stem-cell transplant to be manufactured from the same mobilized collection, or provide a means by which previously cryopreserved mobilized units may be utilised, noting frequently lower cumulative chemotherapy exposure in historically cryopreserved T-cells.
    CAR T-Cell Therapy
    |
    CD8 (cluster of differentiation 8) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • IL15 (Interleukin 15) • IL7 (Interleukin 7)
    |
    CD33 expression
    |
    CART-33